

Gene Fusion Testing Market - A Global and Regional Analysis: Focus on by Category, Technology, Indication, End User, and Region - Analysis and Forecast, 2023-2033

<https://marketpublishers.com/r/GE9346538DC6EN.html>

Date: August 2023

Pages: 239

Price: US\$ 5,500.00 (Single User License)

ID: GE9346538DC6EN

Abstracts

Global Gene Fusion Testing Market Industry Overview

The global gene fusion testing market was valued at \$255.3 million in 2022 and is anticipated to reach \$897.6 million by 2033, witnessing a CAGR of 12.25% during the forecast period 2023-2033. The global gene fusion testing market is expected to be driven by the rising utilization of gene fusion testing in the development of targeted therapies.

Market Lifecycle Stage

The global gene fusion testing market is in progressing phase. The gene fusion testing market is experiencing rapid growth due to the rising cancer incidence because of gene fusion mutations. The demand for early detection, precise selection of targeted therapies, personalized medicine approaches, and the growing recognition and implementation of gene fusion testing in clinical settings all contribute to the escalating need for these diagnostic tests in cancer care.

Impact

Gene fusion testing is a diagnostic method that involves molecular analysis to detect and examine genetic abnormalities called gene fusions. Gene fusions arise when two distinct genes from different chromosomal locations become abnormally joined, resulting in a hybrid gene formation. This fusion can trigger the synthesis of abnormal

proteins or cause changes in gene expression, potentially contributing to the development of diverse diseases, including specific types of cancer. The progression of cancer is influenced by a variety of genetic changes, encompassing mutations, deletions, gene fusions, amplifications, and rearrangements. In addition, the entry of several established players, such as Amoy Diagnostics Co., Ltd., Arima Genomics, Biocartis, Biocare Medical, LLC, Danaher Corporation, F. Hoffmann-La Roche Ltd, Guardant Health, Inc., Illumina, Inc., Myriad Genetics, Inc., and others, is expected to aid the market growth.

Reducing the need for time-consuming and expensive laboratory assays, AI-powered prediction models can help identify patients who should receive further tests for diagnosis first. These models could identify novel, previously undetected gene fusion events, enhancing the comprehension of the genomic environment of malignancies and assisting in the design of targeted therapeutics.

Market Segmentation:

Segmentation 1: by Category

Research

Diagnostic

Research to Continue its Dominance in the by Category Segment

Based on category type, the research segment dominated the global gene fusion testing market in FY2022. The increasing adoption of kits, assays, and accessories contributed to the prominence of the research segment. Research use assays and kits in gene fusion testing are specifically designed and intended for use in research settings rather than for diagnostic purposes. These assays and kits are valuable tools for researchers and scientists who are studying gene fusions and their implications in various diseases, particularly cancer.

Segmentation 2: by Technology

NGS

FISH

PCR

IHC

Next-Generation Sequencing Segment to Hold Major Share in the Global Gene Fusion Testing Market (by Technology)

Based on technology, the NGS segment dominated the global gene fusion testing market in FY2022. Next-generation sequencing (NGS), plays a significant role in gene fusion testing. It is a powerful and advanced technology used to analyze DNA and RNA sequences with high throughput and accuracy. In the context of gene fusion testing, NGS allows for the comprehensive examination of genes and their rearrangements, enabling the identification of fusion events between different genes.

Segmentation 3: by Indication

Solid Tumors

Hematological Malignancies

Solid Tumors Segment to Hold Major Share in the Global Gene Fusion Testing Market (by Indication)

Based on indication, the global gene fusion testing market was dominated by the solid tumors segment in FY2022. In the field of oncology, gene fusion testing in solid tumors holds significant importance within molecular diagnostics. Its primary objective is to pinpoint particular gene fusions arising from chromosomal rearrangements or translocations within tumor cells. These gene fusions can generate abnormal fusion proteins that significantly contribute to the advancement and evolution of solid tumors.

Segmentation 4: by End User

Pharmaceutical and Biotechnology Companies

Hospitals and Diagnostic Laboratories

Academic and Research Centers

Pharmaceutical and Biotechnology Companies to Continue its Dominance in the End User Segment

Based on end user, the pharmaceutical and biotechnology companies segment accounted for the largest share of the global gene fusion testing market in FY2022. Pharmaceutical and biotechnology companies hold an important position in the gene fusion testing market, utilizing their expertise and resources to drive innovation and propel advancements in this rapidly evolving field. They are aware of the immense potential of gene fusion testing in revolutionizing cancer diagnostics and treatment approaches.

Segmentation 5: by Region

North America

Europe

Asia-Pacific

Latin America

Rest-of-the-World

North America held the largest share of 49.64% in 2022 in the global gene fusion testing market, owing to the presence of most key players and rising funding in the region.

Demand - Drivers and Limitations

Market Demand Drivers:

Rising Cancer Incidence Due to Gene Fusion Mutations

Increasing Utilization of Gene Fusion Testing in the Development of Targeted Therapies

Global Rise in Research Grants Dedicated to Cancer Screening and Prevention Efforts

Market Restraints:

Complexity of Testing Process

Lack of Standardization and Reimbursement Barriers

Market Opportunities:

Increasing Demand of Gene Fusion Testing in Clinical Research

Leveraging Artificial Intelligence to Predict Gene Fusion Status in Several Cancer Type

How can this report add value to an organization?

Workflow/Innovation Strategy: The gene fusion testing market (by indication) has been segmented into solid tumors and hematological malignancies. Moreover, the study provides the reader with a detailed understanding of the different indication of gene fusion testing in solid tumors.

Growth/Marketing Strategy: Gene fusion testing is a molecular diagnostic method employed to identify and analyze distinct genetic alterations in cancer cells. It arises when two distinct genes, typically from different chromosomes, abnormally join together, giving rise to a hybrid gene that generates a unique protein with modified functions.

Competitive Strategy: Key players in the global gene fusion testing market have been analyzed and profiled in the study, including manufacturers. Moreover, a detailed competitive benchmarking of the players operating in the global gene fusion testing market has been done to help the reader understand how players stack against each other, presenting a clear market landscape.

Key Market Players and Competition Synopsis

The gene fusion testing market encompasses the healthcare industry segment focused on developing, producing, and commercializing tests and technologies designed to detect and analyze gene fusions. Gene fusion testing involves the identification of abnormal fusion events where two separate genes join together, leading to the formation of fusion proteins with modified functions. These genetic alterations are commonly associated with various diseases, particularly cancer. In this study, several types of fundamental technologies have been examined that have facilitated these advances, namely, polymerase chain reaction (PCR), next-generation sequencing (NGS), immunohistochemistry (IHC), fluorescence in-situ hybridization (FISH). The global gene fusion testing market is strongly driven by the continuous introduction of advanced technologies as well as increased investments and funding from both the government and private sectors.

Key Companies Profiled:

Amoy Diagnostics Co., Ltd.

ArcherDX (Integrated DNA Technologies, Inc.)

Arima Genomics

Biocartis

Biocare Medical, LLC

F. Hoffmann-La Roche Ltd

Guardant Health, Inc

Illumina, Inc.

Myriad Genetics, Inc.

Natera, Inc.

NeoGenomics, Inc.

OncoDNA

QIAGEN N.V.

Quest Diagnostics Incorporated.

Thermo Fisher Scientific Inc.

Contents

1 PRODUCT DEFINITION

1.1 Inclusion and Exclusion Criteria

2 MARKET SCOPE

2.1 Scope of the Study

2.2 Key Questions Answered in the Report

3 RESEARCH METHODOLOGY

4 MARKET OVERVIEW

4.1 Introduction to Gene Fusion Testing

4.1.1 Different Technologies for Gene Fusion Testing

4.1.2 Advantages and Limitations of Gene Fusion Testing

4.1.3 Current Market Size and Future Growth Potential, \$Million, 2022-2033

4.1.3.1 Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion vs. Other Gene Fusions

4.1.4 Role of Artificial Intelligence (AI) and Machine Learning (ML) in Gene Fusion Testing

4.1.5 Reimbursement Landscape

4.2 Stakeholder's Survey Response

4.2.1 Awareness of Gene Fusion Testing

4.2.2 Familiarity with the NGS Offerings of the Following Companies

4.2.3 Adoption and Barriers for Gene Fusion Testing

5 INDUSTRY OUTLOOK

5.1 Regulatory Landscape

5.1.1 Legal Requirements and Frameworks in the U.S.

5.1.1.1 CMS Regulation (Reimbursement Scenario)

5.1.1.2 Marketing Authorization

5.1.2 Legal Requirements and Frameworks in Europe

5.1.3 Legal Requirements and Frameworks in Asia-Pacific

5.1.3.1 Legal Requirements and Framework in China

5.1.3.2 Legal Requirements and Framework in Japan

6 GLOBAL GENE FUSION TESTING MARKET: MARKET DYNAMICS

6.1 Market Drivers

6.1.1 Rising Cancer Incidence due to Gene Fusion Mutations

6.1.2 Increasing Utilization of Gene Fusion Testing in the Development of Targeted Therapies

6.1.3 Global Rise in Research Grants Dedicated to Cancer Screening and Prevention Efforts

6.1.4 Impact Analysis

6.2 Business Restraints

6.2.1 Complexity of Testing Process

6.2.2 Lack of Standardization and Reimbursement Barriers

6.2.3 Impact Analysis

6.3 Business Opportunities

6.3.1 Increasing Demand for Gene Fusion Testing in Clinical Research

6.3.2 Leveraging Artificial Intelligence to Predict Gene Fusion Status in Several Cancer Types

7 GLOBAL GENE FUSION TESTING MARKET: COMPETITIVE INSIGHTS

7.1 Overview

7.2 Key Strategies and Developments

7.2.1 Product Approvals and Launches

7.2.2 Partnerships and Collaborations

7.2.3 Mergers and Acquisitions

7.2.4 Other Developments

7.3 Market Share Analysis

7.3.1 By Company

7.4 Growth-Share Analysis

7.4.1 By Company

7.4.2 By Technology

7.4.3 By Indication

7.4.4 By End User

8 GLOBAL GENE FUSION TESTING MARKET (BY CATEGORY), VALUE (\$MILLION), 2022-2033

8.1 Overview

- 8.2 Research
- 8.3 Diagnostic

9 GLOBAL GENE FUSION TESTING (BY TECHNOLOGY), VALUE (\$MILLION), 2022-2033

- 9.1 Overview
- 9.2 Next-Generation Sequencing (NGS)
- 9.3 Fluorescence In-Situ Hybridization (FISH)
- 9.4 Polymerase Chain Reaction (PCR)
- 9.5 Immunohistochemistry (IHC)

10 GLOBAL GENE FUSION TESTING MARKET (BY INDICATION), VALUE (\$MILLION), 2022-2033

- 10.1 Overview
- 10.2 Solid Tumors
 - 10.2.1 Lung Cancer
 - 10.2.2 Breast Cancer
 - 10.2.3 Colorectal Cancer
 - 10.2.4 Thyroid Cancer
 - 10.2.5 Others
- 10.3 Hematological Malignancies

11 GLOBAL GENE FUSION TESTING MARKET (BY END USER), VALUE (\$MILLION), 2022-2033

- 11.1 Overview
- 11.2 Pharmaceutical and Biotechnology Companies
- 11.3 Hospitals and Diagnostic Laboratories
- 11.4 Research and Academic Centers

12 GLOBAL GENE FUSION TESTING MARKET (BY REGION), VALUE (\$MILLION), 2022-2033

- 12.1 Overview
- 12.2 North America
 - 12.2.1 North America Gene Fusion Testing Market, by Indication
 - 12.2.2 North America Gene Fusion Testing Market (by Country)

12.2.2.1 U.S.

12.2.2.1.1 U.S. Gene Fusion Testing Market (by Indication)

12.2.2.2 Canada

12.2.2.2.1 Canada Gene Fusion Testing Market (by Indication)

12.3 Europe

12.3.1 Europe Gene Fusion Testing Market, by Indication

12.3.2 Europe Gene Fusion Testing Market (by Country)

12.3.2.1 Germany

12.3.2.1.1 Germany Gene Fusion Testing Market (by Indication)

12.3.2.2 France

12.3.2.2.1 France Gene Fusion Testing Market (by Indication)

12.3.2.3 U.K.

12.3.2.3.1 U.K. Gene Fusion Testing Market (by Indication)

12.3.2.4 Italy

12.3.2.4.1 Italy Gene Fusion Testing Market (by Indication)

12.3.2.5 Spain

12.3.2.5.1 Spain Gene Fusion Testing Market (by Indication)

12.3.2.6 Netherlands

12.3.2.6.1 Netherlands Gene Fusion Testing Market (by Indication)

12.3.2.7 Rest-of-Europe

12.3.2.7.1 Rest-of-Europe Gene Fusion Testing Market (by Indication)

12.4 Asia-Pacific

12.4.1 Asia-Pacific Gene Fusion Testing Market, by Indication

12.4.2 Asia-Pacific Gene Fusion Testing Market (by Country)

12.4.2.1 China

12.4.2.1.1 China Gene Fusion Testing Market (by Indication)

12.4.2.2 Japan

12.4.2.2.1 Japan Gene Fusion Testing Market (by Indication)

12.4.2.3 India

12.4.2.3.1 India Gene Fusion Testing Market (by Indication)

12.4.2.4 Australia

12.4.2.4.1 Australia Gene Fusion Testing Market (by Indication)

12.4.2.5 South Korea

12.4.2.5.1 South Korea Gene Fusion Testing Market (by Indication)

12.4.2.6 Rest-of-Asia-Pacific

12.4.2.6.1 Rest-of-Asia-Pacific Gene Fusion Testing Market (by Indication)

12.5 Latin America

12.5.1 Latin America Gene Fusion Testing Market, by Indication

12.5.2 Latin America Gene Fusion Testing Market (by Country)

12.5.2.1 Brazil

12.5.2.1.1 Brazil Gene Fusion Testing Market (by Indication)

12.5.2.2 Mexico

12.5.2.2.1 Mexico Gene Fusion Testing Market (by Indication)

12.5.2.3 Rest-of-Latin America

12.5.2.3.1 Rest-of-Latin America Gene Fusion Testing Market (by Indication)

12.6 Rest-of-the-World

12.6.1 Rest-of-the-World Gene Fusion Testing Market (by Indication)

13 MARKETS - COMPETITIVE BENCHMARKING & COMPANY PROFILES

13.1 Overview

13.2 Amoy Diagnostics Co., Ltd.

13.2.1 Company Overview

13.2.2 Role of Amoy Diagnostics Co., Ltd. in the Global Gene Fusion Testing Market

13.2.3 Key Competitors

13.2.4 Recent Developments

13.2.5 Analyst Perspective

13.3 ArcherDX (Integrated DNA Technologies, Inc.)

13.3.1 Company Overview

13.3.2 Role of ArcherDX (Integrated DNA Technologies, Inc.) in the Global Gene Fusion Testing Market

13.3.3 Key Competitors

13.3.4 Recent Developments

13.3.5 Analyst Perspective

13.4 Arima Genomics

13.4.1 Company Overview

13.4.2 Role of Arima Genomics in the Global Gene Fusion Testing Market

13.4.3 Key Competitors

13.4.4 Recent Developments

13.4.5 Analyst Perspective

13.5 Biocartis

13.5.1 Company Overview

13.5.2 Role of Biocartis in the Global Gene Fusion Testing Market

13.5.3 Key Competitors

13.5.4 Recent Developments

13.5.5 Financials

13.5.6 Key Insights about the Financial Health of the Company

13.5.7 Analyst Perspective

13.6 Biocare Medical, LLC

13.6.1 Company Overview

13.6.2 Role of Biocare Medical, LLC in the Gene Fusion Testing Market

13.6.3 Key Competitors

13.6.4 Recent Developments

13.6.5 Analyst Perspective

13.7 F. Hoffmann-La Roche Ltd

13.7.1 Company Overview

13.7.2 Role of F. Hoffmann-La Roche Ltd in the Global Gene Fusion Testing Market

13.7.3 Key Competitors

13.7.4 Recent Developments

13.7.5 Financials

13.7.6 Key Insights about the Financial Health of the Company

13.7.7 Analyst Perspective

13.8 Guardant Health, Inc

13.8.1 Company Overview

13.8.2 Role of Guardant Health, Inc in the Global Gene Fusion Testing Market

13.8.3 Key Competitors

13.8.4 Financials

13.8.5 Key Insights about the Financial Health of the Company

13.8.6 Analyst Perspective

13.9 Illumina, Inc.

13.9.1 Company Overview

13.9.2 Role of Illumina, Inc. in the Global Gene Fusion Testing Market

13.9.3 Key Competitors

13.9.4 Recent Developments

13.9.5 Financials

13.9.6 Key Insights about the Financial Health of the Company

13.9.7 Analyst Perspective

13.1 Myriad Genetics, Inc.

13.10.1 Company Overview

13.10.2 Role of Myriad Genetics, Inc. in the Global Gene Fusion Testing Market

13.10.3 Key Competitors

13.10.4 Recent Developments

13.10.5 Financials

13.10.6 Key Insights about the Financial Health of the Company

13.10.7 Analyst Perspective

13.11 Natera, Inc.

13.11.1 Company Overview

- 13.11.2 Role of Natera, Inc. in the Global Gene Fusion Testing Market
- 13.11.3 Key Competitors
- 13.11.4 Financials
- 13.11.5 Key Insights about the Financial Health of the Company
- 13.11.6 Analyst Perspective
- 13.12 NeoGenomics, Inc.
 - 13.12.1 Company Overview
 - 13.12.2 Role of NeoGenomics, Inc. in the Global Gene Fusion Testing Market
 - 13.12.3 Key Competitors
 - 13.12.4 Recent Developments
 - 13.12.5 Financials
 - 13.12.6 Key Insights about the Financial Health of the Company
 - 13.12.7 Analyst Perspective
- 13.13 OncoDNA
 - 13.13.1 Company Overview
 - 13.13.2 Role of OncoDNA in the Gene Fusion Testing Market
 - 13.13.3 Key Competitors
 - 13.13.4 Recent Developments
 - 13.13.5 Analyst Perspective
- 13.14 QIAGEN N.V.
 - 13.14.1 Company Overview
 - 13.14.2 Role of QIAGEN N.V. in the Global Gene Fusion Testing Market
 - 13.14.3 Key Competitors
 - 13.14.4 Recent Developments
 - 13.14.5 Financials
 - 13.14.6 Key Insights about the Financial Health of the Company
 - 13.14.7 Analyst Perspective
- 13.15 Quest Diagnostics Incorporated.
 - 13.15.1 Company Overview
 - 13.15.2 Role of Quest Diagnostics Incorporated. in the Global Gene Fusion Testing Market
 - 13.15.3 Key Competitors
 - 13.15.4 Financials
 - 13.15.5 Analyst Perspective
- 13.16 Thermo Fisher Scientific Inc.
 - 13.16.1 Company Overview
 - 13.16.2 Role of Thermo Fisher Scientific Inc. in the Global Gene Fusion Testing Market
 - 13.16.3 Key Competitors

13.16.4 Recent Developments

13.16.5 Financials

13.16.6 Key Insights about the Financial Health of the Company

13.16.7 Analyst Perspective

List Of Figures

LIST OF FIGURES

- Figure 1: Global Gene Fusion Testing Market, \$Million, 2022-2033
- Figure 2: Global Gene Fusion Testing Market: Drivers, Restraints, and Opportunities
- Figure 3: Global Gene Fusion Testing Market (by Category), \$Million, 2022-2033
- Figure 4: Global Gene Fusion Testing Market (by Technology), \$Million, 2022-2033
- Figure 5: Global Gene Fusion Testing Market (by Indication), \$Million, 2022-2033
- Figure 6: Global Gene Fusion Testing Market (by Region), \$Million, 2022 and 2033
- Figure 7: Global Gene Fusion Testing Market Segmentation
- Figure 8: Global Gene Fusion Testing Market: Research Methodology
- Figure 9: Primary Research Methodology
- Figure 10: Bottom-Up Approach (Segment-Wise Analysis)
- Figure 11: Top-Down Approach (Segment-Wise Analysis)
- Figure 12: Different Approaches to Study Gene Fusion
- Figure 13: Different Techniques Used in Gene Fusion Testing
- Figure 14: Global Gene Fusion Testing Market, \$Million, 2022-2033
- Figure 15: Artificial Intelligence and Machine Learning in Gene Fusion Testing
- Figure 16: SOPHiA DDM RNAtarget Technology Workflow
- Figure 17: Awareness to the Concept of Gene Fusion Testing
- Figure 18: Familiarity with NGS Offerings by Key Market Players for Gene Fusion Testing
- Figure 19: Perceived Importance of Key Drivers to Improve Gene Fusion Testing Adoption
- Figure 20: Agreement Level with Key Barriers to Gene Fusion Testing Adoption
- Figure 21: Steps Involved in FDA Regulation
- Figure 22: FDA Guidelines for CDx Approval
- Figure 23: Criteria for CMS Coverage/Reimbursement
- Figure 24: Steps for Obtaining Marketing Authorization
- Figure 25: Europe In Vitro Diagnostic Devices Regulation Regulatory Process
- Figure 26: Workflow for Medical Device Regulations
- Figure 27: Estimated Number of New Cancer Cases, 2020 and 2030
- Figure 28: Clinical Trials Based on Gene Fusion Testing
- Figure 29: Share of Key Developments, January 2020-July 2023
- Figure 30: Number of Product Approvals and Launches (by Company), January 2020 to July 2023
- Figure 31: Partnerships and Collaborations, January 2020-July 2023
- Figure 32: Mergers and Acquisitions, January 2020-July 2023

Figure 33: Other Developments, January 2020-July 2023

Figure 34: Global Fusion Testing Market, Company Share Analysis, % Share, 2022

Figure 35: Growth-Share Analysis for Global Gene Fusion Testing Market (by Company), 2021-2022

Figure 36: Growth-Share Analysis for Global Gene Fusion Testing Market (by Technology), 2022-2033

Figure 37: Growth-Share Analysis for Global Gene Fusion Testing Market (by Indication), 2022-2033

Figure 38: Growth-Share Analysis for Global Gene Fusion Testing Market (by End User), 2022-2033

Figure 39: Global Gene Fusion Testing Market (by Category)

Figure 40: Share of Global Gene Fusion Testing Market (by Category), \$Million, 2022 and 2033

Figure 41: Global Gene Fusion Testing Market (Research), \$Million, 2022-2033

Figure 42: Global Gene Fusion Testing Market (Diagnostic), \$Million, 2022-2033

Figure 43: Global Gene Fusion Testing Market (by Technology)

Figure 44: Share of Global Gene Fusion Testing Market (by Technology), \$Million, 2022 and 2033

Figure 45: Global Gene Fusion Testing Market (Next-Generation Sequencing), \$Million, 2022-2033

Figure 46: Global Gene Fusion Testing Market (Fluorescence In-Situ Hybridization), \$Million, 2022-2033

Figure 47: Global Gene Fusion Testing Market (Polymerase Chain Reaction), \$Million, 2022-2033

Figure 48: Global Gene Fusion Testing Market (Immunohistochemistry), \$Million, 2022-2033

Figure 49: Global Gene Fusion Testing Market (by Indication)

Figure 50: Share of Global Gene Fusion Testing Market (by Indication), \$Million, 2022 and 2033

Figure 51: Global Gene Fusion Testing Market (by Solid Tumors), \$Million, 2022 and 2033

Figure 52: Global Gene Fusion Testing Market (Solid Tumors), \$Million, 2022-2033

Figure 53: Global Gene Fusion Testing Market (Lung Cancer), \$Million, 2022-2033

Figure 54: Global Gene Fusion Testing Market (Breast Cancer), \$Million, 2022-2033

Figure 55: Global Gene Fusion Testing Market (Colorectal Cancer), \$Million, 2022-2033

Figure 56: Global Gene Fusion Testing Market (Thyroid Cancer), \$Million, 2022-2033

Figure 57: Global Gene Fusion Testing Market (Others), \$Million, 2022-2033

Figure 58: Global Gene Fusion Testing Market (Hematological Malignancies), \$Million, 2022-2033

Figure 59: Global Gene Fusion Testing Market (by End User)

Figure 60: Share of Global Gene Fusion Testing Market (by End User), \$Million, 2022 and 2033

Figure 61: Global Gene Fusion Testing Market (Pharmaceutical and Biotechnology Companies), \$Million, 2022-2033

Figure 62: Global Gene Fusion Testing Market (Hospitals and Diagnostic Laboratories), \$Million, 2022-2033

Figure 63: Global Gene Fusion Testing Market (Research and Academic Centers), \$Million, 2022-2033

Figure 64: Global Gene Fusion Testing Market (by Region), \$Million, 2022 and 2033

Figure 65: North America Gene Fusion Testing Market, \$Million, 2023-2033

Figure 66: North America: Market Dynamics

Figure 67: North America Gene Fusion Testing Market (by Indication), \$Million, 2022-2033

Figure 68: North America Gene Fusion Testing Market (by Solid Tumors), \$Million, 2022-2033

Figure 69: U.S. Gene Fusion Testing Market, \$Million, 2022-2033

Figure 70: U.S. Gene Fusion Testing Market (by Indication), \$Million, 2022-2033

Figure 71: U.S. Gene Fusion Testing Market (by Solid Tumors), \$Million, 2022-2033

Figure 72: Canada Gene Fusion Testing Market, \$Million, 2022-2033

Figure 73: Canada Gene Fusion Testing Market (by Indication), \$Million, 2022-2033

Figure 74: Canada Gene Fusion Testing Market (by Solid Tumors), \$Million, 2022-2033

Figure 75: Europe Gene Fusion Testing Market, \$Million, 2022-2033

Figure 76: Europe: Market Dynamics

Figure 77: Europe Gene Fusion Testing Market (by Indication), \$Million, 2022-2033

Figure 78: Europe Gene Fusion Testing Market (by Solid Tumors), \$Million, 2022-2033

Figure 79: Germany Gene Fusion Testing Market, \$Million, 2022-2033

Figure 80: Germany Gene Fusion Testing Market (by Indication), \$Million, 2022-2033

Figure 81: Germany Gene Fusion Testing Market (by Solid Tumors), \$Million, 2022-2033

Figure 82: France Gene Fusion Testing Market, \$Million, 2022-2033

Figure 83: France Gene Fusion Testing Market (by Indication), \$Million, 2022-2033

Figure 84: France Gene Fusion Testing Market (by Solid Tumors), \$Million, 2022-2033

Figure 85: U.K. Gene Fusion Testing Market, \$Million, 2022-2033

Figure 86: U.K. Gene Fusion Testing Market (by Indication), \$Million, 2022-2033

Figure 87: U.K. Gene Fusion Testing Market (by Solid Tumors), \$Million, 2022-2033

Figure 88: Italy Gene Fusion Testing Market, \$Million, 2022-2033

Figure 89: Italy Gene Fusion Testing Market (by Indication), \$Million, 2022-2033

Figure 90: Italy Gene Fusion Testing Market (by Solid Tumors), \$Million, 2022-2033

- Figure 91: Spain Gene Fusion Testing Market, \$Million, 2022-2033
- Figure 92: Spain Gene Fusion Testing Market (by Indication), \$Million, 2022-2033
- Figure 93: Spain Gene Fusion Testing Market (by Solid Tumors), \$Million, 2022-2033
- Figure 94: Netherlands Gene Fusion Testing Market, \$Million, 2022-2033
- Figure 95: Netherlands Gene Fusion Testing Market (by Indication), \$Million, 2022-2033
- Figure 96: Netherlands Gene Fusion Testing Market (by Solid Tumors), \$Million, 2022-2033
- Figure 97: Rest-of-Europe Gene Fusion Testing Market, \$Million, 2022-2033
- Figure 98: Rest-of-Europe Gene Fusion Testing Market (by Indication), \$Million, 2022-2033
- Figure 99: Rest-of-Europe Gene Fusion Testing Market (by Solid Tumors), \$Million, 2022-2033
- Figure 100: Asia-Pacific Gene Fusion Testing Market, \$Million, 2022-2033
- Figure 101: Asia-Pacific: Market Dynamics
- Figure 102: Asia-Pacific Gene Fusion Testing Market (by Indication), \$Million, 2022-2033
- Figure 103: Asia-Pacific Gene Fusion Testing Market (by Solid Tumors), \$Million, 2022-2033
- Figure 104: China Gene Fusion Testing Market, \$Million, 2022-2033
- Figure 105: China Gene Fusion Testing Market (by Indication), \$Million, 2022-2033
- Figure 106: China Gene Fusion Testing Market (by Solid Tumors), \$Million, 2022-2033
- Figure 107: Japan Gene Fusion Testing Market, \$Million, 2022-2033
- Figure 108: Japan Gene Fusion Testing Market (by Indication), \$Million, 2022-2033
- Figure 109: Japan Gene Fusion Testing Market (by Solid Tumors), \$Million, 2022-2033
- Figure 110: India Gene Fusion Testing Market, \$Million, 2022-2033
- Figure 111: India Gene Fusion Testing Market (by Indication), \$Million, 2022-2033
- Figure 112: India Gene Fusion Testing Market (by Solid Tumors), \$Million, 2022-2033
- Figure 113: Australia Gene Fusion Testing Market, \$Million, 2022-2033
- Figure 114: Australia Gene Fusion Testing Market (by Indication), \$Million, 2022-2033
- Figure 115: Australia Gene Fusion Testing Market (by Solid Tumors), \$Million, 2022-2033
- Figure 116: South Korea Gene Fusion Testing Market, \$Million, 2022-2033
- Figure 117: South Korea Gene Fusion Testing Market (by Indication), \$Million, 2022-2033
- Figure 118: South Korea Gene Fusion Testing Market (by Solid Tumors), \$Million, 2022-2033
- Figure 119: Rest-of-Asia-Pacific Gene Fusion Testing Market, \$Million, 2022-2033
- Figure 120: Rest-of-Asia-Pacific Gene Fusion Testing Market (by Indication), \$Million, 2022-2033

Figure 121: Rest-of-Asia-Pacific Gene Fusion Testing Market (by Solid Tumors), \$Million, 2022-2033

Figure 122: Latin America Gene Fusion Testing Market, \$Million, 2023-2033

Figure 123: Latin America: Market Dynamics

Figure 124: Latin America Gene Fusion Testing Market (by Indication), \$Million, 2022-2033

Figure 125: Latin America Gene Fusion Testing Market (by Solid Tumors), \$Million, 2022-2033

Figure 126: Brazil Gene Fusion Testing Market, \$Million, 2022-2033

Figure 127: Brazil Gene Fusion Testing Market (by Indication), \$Million, 2022-2033

Figure 128: Brazil Gene Fusion Testing Market (by Solid Tumors), \$Million, 2022-2033

Figure 129: Mexico Gene Fusion Testing Market, \$Million, 2022-2033

Figure 130: Mexico Gene Fusion Testing Market (by Indication), \$Million, 2022-2033

Figure 131: Mexico Gene Fusion Testing Market (by Solid Tumors), \$Million, 2022-2033

Figure 132: Rest-of-Latin America Gene Fusion Testing Market, \$Million, 2022-2033

Figure 133: Rest-of-Latin America Gene Fusion Testing Market (by Indication), \$Million, 2022-2033

Figure 134: Rest-of-Latin America Gene Fusion Testing Market (by Solid Tumors), \$Million, 2022-2033

Figure 135: Rest-of-the-World Gene Fusion Testing Market, \$Million, 2022-2033

Figure 136: Rest-of-the-World Gene Fusion Testing Market (by Indication), \$Million, 2022-2033

Figure 137: Rest-of-the-World Gene Fusion Testing Market (by Solid Tumors), \$Million, 2022-2033

Figure 138: Global Gene Fusion Testing Market (by Total Number of Companies Profiled)

Figure 139: Amoy Diagnostics Co., Ltd.: Product Portfolio

Figure 140: ArcherDX (Integrated DNA Technologies, Inc.): Product Portfolio

Figure 141: Arima Genomics: Product Portfolio

Figure 142: Biocartis: Product Portfolio

Figure 143: Biocartis: Overall Financials, \$Million, 2020-2022

Figure 144: Biocartis: Revenue (by Segment), \$Million, 2020-2022

Figure 145: Biocartis: Revenue (by Region), \$Million, 2020-2022

Figure 146: Biocartis: R&D Expenditure, \$Million, 2020-2022

Figure 147: Biocare Medical, LLC: Product Portfolio

Figure 148: Empire Genomics, Inc.: Product Portfolio

Figure 149: F. Hoffmann-La Roche Ltd: Product Portfolio

Figure 150: F. Hoffmann-La Roche Ltd: Product Portfolio

Figure 151: F. Hoffmann-La Roche Ltd: Overall Financials, 2020-2022

- Figure 152: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2020-2022
- Figure 153: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2020-2022
- Figure 154: Guardant Health, Inc: Product Portfolio
- Figure 155: Guardant Health, Inc: Overall Financials, \$Million, 2020-2022
- Figure 156: Guardant Health, Inc: Revenue (by Segment), \$Million, 2020-2022
- Figure 157: Guardant Health, Inc: Revenue (by Region), \$Million, 2020-2022
- Figure 158: Guardant Health, Inc: R&D Expenditure, \$Million, 2020-2022
- Figure 159: Illumina, Inc.: Overall Product Portfolio
- Figure 160: Illumina, Inc.: Overall Financials, \$Million, 2020-2022
- Figure 161: Illumina, Inc.: Revenue (by Segment), \$Million, 2020-2022
- Figure 162: Illumina, Inc.: Revenue (by Region), \$Million, 2020-2022
- Figure 163: Illumina, Inc.: R&D Expenditure, \$Million, 2020-2022
- Figure 164: Myriad Genetics, Inc.: Product Portfolio
- Figure 165: Myriad Genetics, Inc.: Overall Financials, \$Million, 2020-2022
- Figure 166: Myriad Genetics, Inc.: Revenue (by Segment), \$Million, 2020-2022
- Figure 167: Myriad Genetics, Inc.: R&D Expenditure, \$Million, 2020-2022
- Figure 168: Natera, Inc.: Product Portfolio
- Figure 169: Natera, Inc. Overall Financials, \$Million, 2020-2022
- Figure 170: Natera, Inc.: Revenue (by Segment), \$Million, 2020-2022
- Figure 171: Natera, Inc.: Revenue (by Region), \$Million, 2020-2022
- Figure 172: Natera, Inc.: R&D Expenditure, \$Million, 2020-2022
- Figure 173: NeoGenomics, Inc.: Product Portfolio
- Figure 174: NeoGenomics, Inc.: Overall Financials, \$Million, 2020-2022
- Figure 175: NeoGenomics, Inc.: Revenue (by Segment), \$Million, 2020-2022
- Figure 176: NeoGenomics, Inc.: R&D Expenditure, \$Million, 2020-2022
- Figure 177: OncoDNA: Product Portfolio
- Figure 178: QIAGEN N.V.: Product Portfolio
- Figure 179: QIAGEN N.V.: Overall Financials, \$Million, 2020-2022
- Figure 180: QIAGEN N.V.: Revenue (by Segment), \$Million, 2020-2022
- Figure 181: QIAGEN N.V.: Revenue (by Region), \$Million, 2020-2022
- Figure 182: QIAGEN N.V.: R&D Expenditure, \$Million, 2020-2022
- Figure 183: Quest Diagnostics Incorporated.: Product Portfolio
- Figure 184: Quest Diagnostics Incorporated.: Overall Financials, \$Million, 2020-2022
- Figure 185: Quest Diagnostics Incorporated.: Revenue (by Segment), \$Million, 2020-2022
- Figure 186: Thermo Fisher Scientific Inc.: Product Portfolio
- Figure 187: Thermo Fisher Scientific Inc.: Overall Financials, \$Million, 2020-2022
- Figure 188: Thermo Fisher Scientific Inc.: Revenue (by Segment), \$Million, 2020-2022
- Figure 189: Thermo Fisher Scientific Inc.: Revenue (by Region), \$Million, 2020-2022

Figure 190: Thermo Fisher Scientific Inc.: R&D Expenditure, \$Million, 2020-2022

List Of Tables

LIST OF TABLES

Table 1: Global Gene Fusion Testing Market, Impact Analysis

Table 2: Key Questions Answered in the Report

Table 3: Advantages of Gene Fusion Testing

Table 4: Limitations of Gene Fusion Testing

Table 5: NTRK Gene Fusion in Different Types of Cancer

Table 6: Different Types of Gene Fusion

Table 7: Gene Fusion Testing Market: Global Regulatory Scenario

Table 8: Gene Fusion Mutations in Cancer

Table 9: Tissue-Agnostic Targeted Therapies Approved by FDA

Table 10: Global Grants for Cancer Screening

Table 11: Impact Analysis: Business Drivers

Table 12: Gene Fusion Testing Methods: Challenges

Table 13: Impact Analysis: Business Restraints

Table 14: Artificial Intelligence in the Field of Gene Fusion Testing

Table 15: Companies Offering Research Use Products

Table 16: Companies Offering Diagnostic Products

Table 17: NTRK Test Rate Across Several European Countries

I would like to order

Product name: Gene Fusion Testing Market - A Global and Regional Analysis: Focus on by Category, Technology, Indication, End User, and Region - Analysis and Forecast, 2023-2033

Product link: <https://marketpublishers.com/r/GE9346538DC6EN.html>

Price: US\$ 5,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GE9346538DC6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

